# A Trial to Learn if REGN7999 is Safe and Well Tolerated, and How it Works in the Body of Healthy Participants

> **NCT05481333** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 64 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** REGN7999
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05481333
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-24
- **Primary completion:** 2023-08-29
- **Final completion:** 2023-08-29
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2024-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05481333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05481333, "A Trial to Learn if REGN7999 is Safe and Well Tolerated, and How it Works in the Body of Healthy Participants". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05481333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*